American Portfolios Advisors Nektar Therapeutics Transaction History

American Portfolios Advisors

  • $2.36 Trillion
  • Q3 2022

A detailed history of American Portfolios Advisors transactions in Nektar Therapeutics stock. As of the latest transaction made, American Portfolios Advisors holds 230 shares of NKTR stock, worth $158. This represents 0.0% of its overall portfolio holdings.

Number of Shares
230
Holding current value
$158
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023
BUY
$3.04 - $5.14 $699 - $1,182
230 New
230 $736,000
Q4 2021

Mar 21, 2023
BUY
$10.83 - $18.41 $2,707 - $4,602
250 Added 108.7%
480 $6.49 Million
Q3 2021

Mar 22, 2023
BUY
$13.07 - $18.84 $3,267 - $4,710
250 Added 108.7%
480 $8.62 Million
Q2 2021

Mar 22, 2023
BUY
$16.52 - $20.4 $826 - $1,019
50 Added 21.74%
280 $4.81 Million
Q1 2021

Mar 22, 2023
BUY
$16.56 - $25.46 $1,738 - $2,673
105 Added 45.65%
335 $6.7 Million
Q4 2020

Mar 22, 2023
BUY
$15.77 - $19.03 $1,655 - $1,998
105 Added 45.65%
335 $5.7 Million
Q3 2020

Mar 22, 2023
BUY
$16.59 - $24.79 $1,741 - $2,602
105 Added 45.65%
335 $5.56 Million
Q1 2020

Mar 24, 2023
BUY
$14.47 - $27.96 $7,307 - $14,119
505 Added 219.57%
735 $13.1 Million
Q4 2019

Mar 24, 2023
BUY
$15.87 - $23.12 $8,014 - $11,675
505 Added 219.57%
735 $15.9 Million
Q3 2019

Mar 24, 2023
BUY
$16.91 - $36.27 $3,382 - $7,254
200 Added 37.38%
735 $13.4 Million
Q2 2019

Mar 24, 2023
BUY
$31.0 - $36.3 $9,455 - $11,071
305 Added 132.61%
535 $19 Million
Q1 2019

Mar 24, 2023
SELL
$31.58 - $46.35 $1,421 - $2,085
-45 Reduced 8.57%
480 $16.1 Million
Q3 2018

Mar 24, 2023
BUY
$46.46 - $68.49 $13,705 - $20,204
295 Added 128.26%
525 $32 Million
Q2 2018

Mar 24, 2023
BUY
$46.25 - $104.45 $16,418 - $37,079
355 Added 154.35%
585 $28.6 Million

Others Institutions Holding NKTR

# of Institutions
159
Shares Held
128M
Call Options Held
92.7K
Put Options Held
4.9K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $129M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email